Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment

NCT01134640 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT01134640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01134640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Observational
Overall status
Completed
Start date
January 31, 2008
Completion date
November 30, 2010
Enrollment
286 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer